Skip to main content

Novartis

Novartis AG is a Swiss multinational pharmaceutical corporation researching, manufacturing, and marketing innovative prescription therapeutics across cardiovascular, immunology, neuroscience, and oncology therapeutic areas. The company commercializes innovative medicines including Entresto for heart failure, Cosentyx for autoimmune diseases, Kesimpta for multiple sclerosis, and advanced cell and gene therapies like Kymriah and Zolgensma. Main revenue drivers comprise global commercial sales of innovative prescription biopharmaceuticals, targeted oncology drugs, and advanced radieligand therapies. Novartis serves clinical specialists, hospital networks, prescription pharmacies, and patients across Europe, North America, Asia-Pacific, and Latin America. The enterprise holds a world-dominant market position in prescription pharmaceuticals, cardiovascular treatments, and cell and gene therapies. Headquartered in Basel, Switzerland, Novartis AG is listed on the SIX Swiss Exchange and the New York Stock Exchange.

166 of the funds FundTelligence covers report a position in Novartis.

Sector
Health Care
Country
Switzerland
Funds holding it
166
Exposure themes
Multiple, Treatment, Women's Health

Funds holding Novartis

Showing the 8 largest of 166 funds holding it.

Loading...